Yunsuk Choi1, Ki-Bum Won2,3, Hyeon Hui Kang4,5, Hyuk-Jae Change6. 1. Division of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. 2. Division of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea. 3. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. 4. Division of Pulmonary, Critical Care and Sleep Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. khh3822@naver.com. 5. Division of Pulmonary, Critical Care and Sleep Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwando-ro, Dong-gu, Ulsan, 44033, Republic of Korea. khh3822@naver.com. 6. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Yonsei University Health System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. hjchang@yuhs.ac.
Abstract
BACKGROUND: The serum hemoglobin (Hb) level is closely related to adverse clinical outcomes. However, data on the association of Hb levels with subclinical atherosclerosis beyond metabolic abnormalities are limited. METHODS: This study evaluated the association among serum Hb level, metabolic syndrome (MetS), and the risk of carotid plaque formation in asymptomatic adults without a history of major adverse clinical events. RESULTS: A total of 2560 participants (mean age: 60 ± 8 years, 32.9% men) were stratified into four groups based on Hb quartiles, as follows: ≤ 12.8 g/dL (group I), 12.9-13.6 g/dL (group II), 13.7-14.5 g/dL (group III), and ≥ 14.6 g/dL (group IV). The overall prevalence of MetS and carotid plaque was 37.2% and 33.4%, respectively. The prevalence of MetS increased with increasing Hb level (group I: 27.4% vs. group II: 35.9% vs. group III: 42.6% vs. group IV: 44.1%, p < 0.001). The prevalence of carotid plaque was 34.3%, 28.1%, 32.8%, and 39.5% in groups I, II, III, and IV, respectively. Univariate logistic regression analysis showed that MetS was associated with an increased risk of carotid plaque (odds ratio [OR] 1.568, 95% confidence interval [CI] 1.326-1.856, p < 0.001). Only group II showed a lower risk of carotid plaque than group I (OR 0.750, 95% CI 0.596-0.943, p = 0.014). Multiple logistic regression models showed consistent results after adjusting for clinical factors, including MetS and its individual components. CONCLUSION: Serum Hb level is associated with the risk of carotid plaque beyond MetS and its components in a relatively healthy adult population.
BACKGROUND: The serum hemoglobin (Hb) level is closely related to adverse clinical outcomes. However, data on the association of Hb levels with subclinical atherosclerosis beyond metabolic abnormalities are limited. METHODS: This study evaluated the association among serum Hb level, metabolic syndrome (MetS), and the risk of carotid plaque formation in asymptomatic adults without a history of major adverse clinical events. RESULTS: A total of 2560 participants (mean age: 60 ± 8 years, 32.9% men) were stratified into four groups based on Hb quartiles, as follows: ≤ 12.8 g/dL (group I), 12.9-13.6 g/dL (group II), 13.7-14.5 g/dL (group III), and ≥ 14.6 g/dL (group IV). The overall prevalence of MetS and carotid plaque was 37.2% and 33.4%, respectively. The prevalence of MetS increased with increasing Hb level (group I: 27.4% vs. group II: 35.9% vs. group III: 42.6% vs. group IV: 44.1%, p < 0.001). The prevalence of carotid plaque was 34.3%, 28.1%, 32.8%, and 39.5% in groups I, II, III, and IV, respectively. Univariate logistic regression analysis showed that MetS was associated with an increased risk of carotid plaque (odds ratio [OR] 1.568, 95% confidence interval [CI] 1.326-1.856, p < 0.001). Only group II showed a lower risk of carotid plaque than group I (OR 0.750, 95% CI 0.596-0.943, p = 0.014). Multiple logistic regression models showed consistent results after adjusting for clinical factors, including MetS and its individual components. CONCLUSION: Serum Hb level is associated with the risk of carotid plaque beyond MetS and its components in a relatively healthy adult population.
Authors: Scott M Grundy; James I Cleeman; Stephen R Daniels; Karen A Donato; Robert H Eckel; Barry A Franklin; David J Gordon; Ronald M Krauss; Peter J Savage; Sidney C Smith; John A Spertus; Fernando Costa Journal: Circulation Date: 2005-09-12 Impact factor: 29.690
Authors: Tamar S Polonsky; Robyn L McClelland; Neal W Jorgensen; Diane E Bild; Gregory L Burke; Alan D Guerci; Philip Greenland Journal: JAMA Date: 2010-04-28 Impact factor: 56.272
Authors: Vijay Kunadian; Roxana Mehran; A Michael Lincoff; Frederick Feit; Steven V Manoukian; Martial Hamon; David A Cox; George D Dangas; Gregg W Stone Journal: Am J Cardiol Date: 2014-09-28 Impact factor: 2.778
Authors: Peter A McCullough; Denise Barnard; Robert Clare; Stephen J Ellis; Jerome L Fleg; Gregg C Fonarow; Barry A Franklin; Ryan D Kilpatrick; Dalane W Kitzman; Christopher M O'Connor; Ileana L Piña; Udho Thadani; Vinay Thohan; David J Whellan Journal: Clin Cardiol Date: 2013-08-08 Impact factor: 2.882
Authors: Joseph F Polak; Michael J Pencina; Karol M Pencina; Christopher J O'Donnell; Philip A Wolf; Ralph B D'Agostino Journal: N Engl J Med Date: 2011-07-21 Impact factor: 91.245
Authors: James B Young; William T Abraham; Nancy M Albert; Wendy Gattis Stough; Mihai Gheorghiade; Barry H Greenberg; Christopher M O'Connor; Lilin She; Jie Lena Sun; Clyde W Yancy; Gregg C Fonarow Journal: Am J Cardiol Date: 2008-01-15 Impact factor: 2.778
Authors: Hessel F Groenveld; James L Januzzi; Kevin Damman; Jan van Wijngaarden; Hans L Hillege; Dirk J van Veldhuisen; Peter van der Meer Journal: J Am Coll Cardiol Date: 2008-09-02 Impact factor: 24.094